Email Updates

You are here

Home

AVAC's Blog: P-Values

  • Arm advocates with the appropriate facts so that they can drive change in their own countries

    Charles Brown reflects on the important role of advocates in prevention research and what they need to succeed. This post was written for the WhatsUpHIV blog, which reported in real time on the 2014 HIV Research for Prevention conference in Cape Town, South Africa.

    October 30, 2014
    PrEP
    Charles Brown, 2014 AVAC Advocacy Fellow

  • Why we young women had to resort to putting up the Visible Panty Line

    Yvette Raphael critiques researchers' efforts to engage young women at the 2014 HIV Research for Prevention (HIV R4P) conference. She challenges how researchers talk about women "lying" about adherence and expresses frustration at the difficulty of getting these researchers to participate in a conversation about this. This post was written for the WhatsUpHIV blog, which reported in real time on the 2014 HIV Research for Prevention conference in Cape Town, South Africa.

    October 30, 2014
    Microbicides, PrEP
    Yvette Raphael, 2014 AVAC Advocacy Fellow

  • PrEP for a New Era

    PrEP took centerstage at the morning plenaries at HIV R4P—and while the talks were going on, the French research agency announced that the IPERGAY trial of intermittent ("on demand") PrEP would be discontinuing randomization and placebo control after strong preliminary evidence of efficacy. This blog post gives a look at both developments.

    October 29, 2014
    PrEP
    AVAC

  • HIV R4P Conference Day 2 Snapshot

    Greetings from the second day of the HIV R4P conference! Each day AVAC will be providing a dispatch with highlights from the conference. Read on for information about the plenary speeches and individual sessions. And we are tweeting all the latest news and photos. Follow us!

    October 29, 2014
    Combination Prevention

  • Young women influencing the agenda

    Definate Nhamo and Teresia Njoki Otieno report on key conversations around women's HIV prevention. They discuss research findings on adherence in ARV-based prevention trials and the evolving body of evidence on hormonal contraceptive use and HIV risk. They also highlight the perspectives of young women who participated in the conference. This post was written for the WhatsUpHIV blog, which reported in real time on the 2014 HIV Research for Prevention conference in Cape Town, South Africa.

    October 29, 2014
    Hormonal Contraceptives and HIV, Microbicides, PrEP
    Teresia Njoki Otieno, 2014 AVAC Advocacy Fellow
    Definate Nhamo, 2014 AVAC Advocacy Fellow

  • First-ever conference devoted solely to HIV prevention R&D taking place in uncertain funding environment

    In this post (first appearing on Breakthroughs, a blog from GHTC), Emily Donaldson—program coordinator at AVAC—and Tom Harmon—senior policy analyst at the International AIDS Vaccine Initiative (IAVI)—write about the state of HIV prevention research funding as the first-ever conference devoted solely to HIV prevention research and development (R&D) takes place in Cape Town, South Africa, this week.

    October 28, 2014
    General
    Emily Donaldson - AVAC
    Tom Harmon - IAVI

  • HIV R4P Day 1 Snapshot

    Greetings from the first official day of the HIV R4P conference! Each day AVAC will be providing a dispatch with highlights from the conference. Read on for information about the plenary speeches and individual sessions. And we are tweeting all the latest news and photos. Follow us!

    October 28, 2014
    Combination Prevention
    AVAC

  • If It Works, We Should Use It

    Eric Mcheka reacts to a presentation by Mitchell Warren during an advocates' workshop. This post was written for the WhatsUpHIV blog, which reported in real time on the 2014 HIV Research for Prevention conference in Cape Town, South Africa.

    October 28, 2014
    PrEP, Voluntary Medical Male Circumcision
    Eric Mcheka, 2014 AVAC Advocacy Fellow

  • Workshopping Alternative Microbicide Trial Designs

    Clinical trials can only achieve their goals if participants use the product. A trial looking at safety or efficacy can’t gather information or draw conclusions if the trial volunteers choose not to follow the protocol—whether it is taking a drug, using a gel or returning for a follow-up injection of a vaccine.
    October 27, 2014
    , Microbicides
    AVAC

  • An Advocates' Guide to HIV R4P: How to link up on-site and from afar

    The HIV Research for Prevention Conference (HIV R4P) starts on Monday, October 27 in Cape Town, South Africa. We hope that whether on-site or from afar, you will follow along and join the conversation, which will span the range of prevention options (including vaccines, PrEP, microbicides, treatment as prevention, voluntary medical male circumcision and cure) as well as the cross-cutting issues related to trial design and conduct, policy and advocacy.

    October 24, 2014
    Combination Prevention
    AVAC

Pages

view more